Want to see HK:6833 full AI Analyst Report?
Top Page
Sinco Pharmaceuticals Holdings Ltd.
(6833)
Select Model
Select Model
Rating:53Neutral
Price Target:
HK$0.15
▼(-18.33% Downside)
Action:Reiterated
Date:09/10/26
The score is mainly constrained by pressured operating performance (weaker revenue and thin margins) and bearish technical signals (price below key moving averages and negative MACD). A healthier balance sheet and modest valuation (low P/E) partially offset these risks but are not enough to lift the overall profile materially.
Positive Factors
Improving leverage and equity base
Lower leverage and a growing equity base improve financial resilience and reduce pressure on future cash flows. This gives Sinco more flexibility to manage operating volatility, support working-capital needs, and fund business priorities without relying as heavily on external borrowing.
Negative Factors
Sharp revenue contraction
A sharp revenue decline reduces operating scale and can make fixed costs harder to absorb across the business. The reversal from earlier growth raises concern about demand momentum and makes sustained earnings improvement more difficult until top-line performance stabilizes.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving leverage and equity base
Lower leverage and a growing equity base improve financial resilience and reduce pressure on future cash flows. This gives Sinco more flexibility to manage operating volatility, support working-capital needs, and fund business priorities without relying as heavily on external borrowing.
Read all positive factors
Sinco Pharmaceuticals Holdings Ltd. (6833) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$329.33M
Dividend Yield1.15%
Average Volume (3M)52.80K
Price to Earnings (P/E)8.4
Beta (1Y)0.30
Revenue Growth-20.04%
EPS Growth-25.66%
CountryHK
Employees261
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)0.02
Shares Outstanding2,032,890,600
10 Day Avg. Volume75,600
30 Day Avg. Volume52,800
Financial Highlights & Ratios
PEG Ratio-0.62
Price to Book (P/B)0.47
Price to Sales (P/S)0.16
P/FCF Ratio2.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sinco Pharmaceuticals Holdings Ltd. Business Overview & Revenue Model
Company Description
Sinco Pharmaceuticals Holdings Limited operates as an investment holding entity primarily specializing in the marketing, promotion, and distribution channel management of imported pharmaceutical products and medical devices throughout China. Its p...
Sinco Pharmaceuticals Holdings Ltd. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
64
Positive
Cash Flow
52
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.08B | 2.82B | 2.54B | 2.27B | 2.02B |
| Gross Profit | 222.09M | 299.94M | 323.28M | 305.87M | 364.95M |
| EBITDA | 93.45M | 132.60M | 126.01M | 109.01M | 197.69M |
| Net Income | 34.85M | 42.05M | 42.35M | 69.46M | 135.08M |
Balance Sheet | |||||
| Total Assets | 1.85B | 2.00B | 1.89B | 1.42B | 1.23B |
| Cash, Cash Equivalents and Short-Term Investments | 374.53M | 308.32M | 437.92M | 329.14M | 326.05M |
| Total Debt | 183.47M | 350.54M | 251.40M | 192.41M | 340.95M |
| Total Liabilities | 1.15B | 1.34B | 1.26B | 820.52M | 857.88M |
| Stockholders Equity | 694.36M | 662.88M | 628.05M | 603.81M | 374.89M |
Cash Flow | |||||
| Free Cash Flow | 159.71M | -268.05M | 289.16M | 22.39M | 282.19M |
| Operating Cash Flow | 169.49M | -232.88M | 353.70M | 75.08M | 305.71M |
| Investing Cash Flow | -27.09M | -52.87M | -63.63M | -119.27M | -22.73M |
| Financing Cash Flow | -197.24M | 154.59M | -189.73M | 35.04M | -97.11M |
Sinco Pharmaceuticals Holdings Ltd. Technical Analysis
Negative
0.18
Price Trends
0.17
Negative
0.17
Negative
0.18
Negative
Market Momentum
>-0.01
Positive
42.78
Neutral
59.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6833, the sentiment is Negative. The current price of 0.18 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.17, and above the 200-day MA of 0.18, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.78 is Neutral, neither overbought nor oversold. The STOCH value of 59.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6833.
Sinco Pharmaceuticals Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | HK$50.02B | 5.97 | 8.33% | 5.03% | 2.78% | 7.71% | |
61 Neutral | HK$64.61B | 12.78 | 6.21% | 4.66% | 8.02% | -17.74% | |
57 Neutral | HK$594.00M | 10.93 | 7.70% | 6.25% | 14.28% | 0.81% | |
56 Neutral | HK$976.17M | -13.82 | -3.87% | ― | 8.73% | 80.38% | |
53 Neutral | HK$329.33M | 8.38 | 4.33% | 1.15% | -20.04% | -25.66% | |
52 Neutral | HK$245.63M | 18.33 | 1.89% | 7.83% | -13.82% | 112.24% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:6833
Sinco Pharmaceuticals Holdings Ltd.
0.15
-0.09
-37.77%
HK:2607
Shanghai Pharmaceuticals Holding Co
11.51
-0.07
-0.64%
HK:1099
Sinopharm Group Co
15.70
-2.16
-12.09%
HK:9886
Dingdang Health Technology Group Ltd.
0.80
-0.07
-8.62%
HK:1110
Kingworld Medicines Group Ltd.
0.41
-0.15
-26.36%
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
5.50
-0.18
-3.15%
Sinco Pharmaceuticals Holdings Ltd. Corporate Events
Sinco Pharmaceuticals’ Interim Profit Falls as Revenue Declines Despite Margin Improvement
Aug 28, 2026
Sinco Pharmaceuticals reported interim revenue of RMB1.03 billion for the six months ended 30 June 2026, down 13.7% year-on-year, mainly due to weaker sales of pharmaceutical products and a small decline in medical beauty service income. Despite t...
Sinco Pharmaceuticals strengthens board with new independent directors
Aug 28, 2026
Sinco Pharmaceuticals Holdings Ltd. has appointed Mr. Dong Yingjie and Mr. Ye Guowei as independent non-executive directors, effective 28 August 2026, strengthening the company’s board oversight and governance structure. The move is expected...
Sinco Pharmaceuticals Details Board and Committee Structure
Aug 28, 2026
Sinco Pharmaceuticals Holdings Limited has announced the current composition of its board of directors, detailing the executive, non-executive and independent non-executive directors, including the chairman and lead independent director. The compa...
Sinco Pharmaceuticals Sets August Board Meeting to Review Interim Results and Dividend
Aug 18, 2026
Sinco Pharmaceuticals Holdings Limited has scheduled a board meeting for 28 August 2026 to review and approve the interim results of the company and its subsidiaries for the six months ended 30 June 2026. The board will also consider whether to re...
Sinco Pharmaceuticals Restructures Guarantees Following Founder’s Passing
Jul 26, 2026
Sinco Pharmaceuticals Holdings Ltd. announced the passing of its founder, controlling shareholder and former chairman, Mr. Huang Xiangbin, on 24 July 2026, and the board expressed deep appreciation for his role in building the company while extend...
Sinco Pharmaceuticals Details Shareholder Guarantee Fees and Market-Based Terms
Jul 15, 2026
Sinco Pharmaceuticals Holdings Ltd. has disclosed additional information on its continuing connected transaction involving a guarantee agreement with major shareholder Mr. Huang Xiangbin. The company reports it has paid approximately RMB13.58 mill...
Sinco Pharmaceuticals Shifts Guarantee Fee Payments to Quarterly Basis
Jun 22, 2026
Sinco Pharmaceuticals has amended the payment terms of the guarantee fees it pays to its controlling shareholder, Mr. Huang, for providing guarantees on the group’s loan facilities. Under a newly signed side letter, the fees, capped annually...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.